Anosmia and / or Ageusia in COVID-19: Timeline, Treatment With Early Corticosteroid and Recovery
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Time to recovery
研究概览
简要总结
Time to recover of Anosmia and / or ageusia and early corticosteroid use
详细描述
In a study of dexamethasone kinetics in two groups of 15 patients with community-acquired pneumonia, one group was treated with dexamethasone 6 mg/day by mouth and the other with 4 mg/day intravenously. The apparent volume of distribution was 1 L/kg in both groups, but the half-life after oral administration was approximately 7 hours, and after intravenous administration 9 hours. The bioavailability of oral dexamethasone was 81% (95% CI = 54-121%). However, the biological half-life of dexamethasone is much longer, of the order of 36-54 h compared with 18-36 h for prednisolone.
Time to recover of Anosmia and / or ageusia and early corticosteroid use
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any case with COVID-19
- •Age more than or equal to 18 years
- •Mild to moderate severity
排除标准
- •Any contra-indication for the interventional drug
- •Mentally disabled cases
研究组 & 干预措施
Early CS
early use of dexamethasone as early as the laboratory confirmation of inflammation.
干预措施: Early-Dexamethasone (Drug)
Late CS
Dexamethasone is to be used lately upon the deterioration of cases
干预措施: Late dexamethazone (Drug)
结局指标
主要结局
Time to recovery
时间窗: one to 6 weeks
Time to recovery from anosmia and / or agusia
次要结局
未报告次要终点